Hancock Whitney Corp Sells 629 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Hancock Whitney Corp reduced its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 11.0% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 5,109 shares of the company’s stock after selling 629 shares during the quarter. Hancock Whitney Corp’s holdings in Amphastar Pharmaceuticals were worth $248,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC increased its holdings in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after buying an additional 273 shares during the period. Innealta Capital LLC acquired a new position in Amphastar Pharmaceuticals during the second quarter valued at approximately $55,000. Blue Trust Inc. lifted its stake in Amphastar Pharmaceuticals by 23.9% during the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares during the last quarter. Asset Management One Co. Ltd. acquired a new stake in shares of Amphastar Pharmaceuticals in the 3rd quarter valued at $78,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after purchasing an additional 301 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Insider Activity

In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. This represents a 6.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares in the company, valued at approximately $3,504,256.23. This trade represents a 3.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 27,533 shares of company stock valued at $1,378,252 over the last quarter. 27.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Piper Sandler dropped their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target on the stock. Finally, StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average target price of $60.33.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $45.21 on Thursday. The stock has a 50-day moving average price of $48.10 and a two-hundred day moving average price of $44.50. Amphastar Pharmaceuticals, Inc. has a 12 month low of $36.56 and a 12 month high of $65.92. The company has a market capitalization of $2.17 billion, a PE ratio of 14.74, a P/E/G ratio of 0.89 and a beta of 0.82. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.